STRIDE Study : The Effects of semaglutide on functional capacity in pith type 2 diabetes and peripheral arterial disease
Recruiting
18 years - 99 years
All
Phase
3
10 participants needed
1 Location
Brief description of study
This is a 52 week, randomized, double-blind, placebo-controlled trial comparing semaglutide 1 mg versus placebo both added to standard of care and administered once weekly in subjects with Type 2 Diabetes Mellitus with Intermittent Claudication.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: type 2 diabetes,peripheral arterial disease,PAD,type 2 diabetes,peripheral arterial disease,PAD
-
Age: 18 years - 99 years
-
Gender: All
Male or Female Type 2 Diabetes 18 years of age or older peripheral arterial disease
Updated on
04 Aug 2024.
Study ID: 848387